A beta 42 is essential for parenchymal and vascular amyloid deposition in mice

Department Neuroscience, Mayo Clinic College of Medicine, Jacksonville, FL 32224, USA.
Neuron (Impact Factor: 15.98). 08/2005; 47(2):191-9. DOI: 10.1016/j.neuron.2005.06.030
Source: PubMed

ABSTRACT Considerable circumstantial evidence suggests that Abeta42 is the initiating molecule in Alzheimer's disease (AD) pathogenesis. However, the absolute requirement for Abeta42 for amyloid deposition has never been demonstrated in vivo. We have addressed this by developing transgenic models that express Abeta1-40 or Abeta1-42 in the absence of human amyloid beta protein precursor (APP) overexpression. Mice expressing high levels of Abeta1-40 do not develop overt amyloid pathology. In contrast, mice expressing lower levels of Abeta1-42 accumulate insoluble Abeta1-42 and develop compact amyloid plaques, congophilic amyloid angiopathy (CAA), and diffuse Abeta deposits. When mice expressing Abeta1-42 are crossed with mutant APP (Tg2576) mice, there is also a massive increase in amyloid deposition. These data establish that Abeta1-42 is essential for amyloid deposition in the parenchyma and also in vessels.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Alzheimer's disease (AD) is the most prevalent form of dementia which affects people older than 60 years of age. In AD, the dysregulation of the amyloid-beta (Aβ) level leads to the appearance of senile plaques which contain Aβ depositions. Aβ is a complex biological molecule which interacts with many types of receptors and/or forms insoluble assemblies and, eventually, its nonphysiological depositions alternate with the normal neuronal conditions. In this situation, AD signs appear and the patients experience marked cognitional disabilities. In general, intellect, social skills, personality, and memory are influenced by this disease and, in the long run, it leads to a reduction in quality of life and life expectancy. Due to the pivotal role of Aβ in the pathobiology of AD, a great deal of effort has been made to reveal its exact role in neuronal dysfunctions and to finding efficacious therapeutic strategies against its adverse neuronal outcomes. Hence, the determination of its different molecular assemblies and the mechanisms underlying its pathological effects are of interest. In the present paper, some of the well-established structural forms of Aβ, its interactions with various receptors and possible molecular and cellular mechanisms underlying its neurotoxicity are discussed. In addition, several Aβ-based rodent models of AD are reviewed. © 2014 S. Karger AG, Basel.
    Medical Principles and Practice 11/2014; 24(1). DOI:10.1159/000369101 · 1.11 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: ?-Secretase proteases have been associated with pathology in Alzheimer disease (AD), but we are just beginning to understand their basic mechanisms and physiological roles. A negative drug trial with a broad spectrum ?-secretase inhibitor in AD patients has severely dampened enthusiasm for the potential of pursuing ?-secretase research therapeutically. This pessimism is unwarranted: analysis of available information presented here demonstrates significant confounds for interpreting the outcome of the trial and argues that the major lessons pertain to broad knowledge gaps that are imperative to fill.
    Cell 11/2014; 159(4):721-6. DOI:10.1016/j.cell.2014.10.016 · 33.12 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The relationship between the pathogenic amyloid beta-peptide species Abeta1-42 and tau pathology has been well studied and suggests that Abeta1-42 can accelerate tau pathology in vitro and in vivo. The manners if any in which Abeta1-40 interacts with tau remains poorly understood. In order to answer this question, we used cell-based system, transgenic fly and transgenic mice as models to study the interaction between Abeta1-42 and Abeta1-40. In our established cellular model, live cell imaging (using confocal microscopy) combined with biochemical data showed that exposure to Abeta1-42 induced cleavage, phosphorylation and aggregation of wild-type/full length tau while exposure to Abeta1-40 didn't. Functional studies with Abeta1-40 were carried out in tau-GFP transgenic flies and showed that Abeta1-42, as previously reported, disrupted cytoskeletal structure while Abeta1-40 had no effect at same dose. To further explore how Abeta1-40 affects tau pathology in vivo, P301S mice (tau transgenic mice) were injected intracerebrally with either Abeta1-42 or Abeta1-40. We found that treatment with Abeta1-42 induced tau phosphorylation, cleavage and aggregation of tau in P301S mice. By contrast, Abeta1-40 injection didn't alter total tau, phospho-tau (recognized by PHF-1) or cleavage of tau, but interestingly, phosphorylation at Ser262 was shown to be significantly decreased after direct inject of Abeta1-40 into the entorhinal cortex of P301S mice. These results demonstrate that Abeta1-40 plays different role in tau pathogenesis compared to Abeta1-42. Abeta1-40 may have a protective role in tau pathogenesis by reducing phosphorylation at Ser262, which has been shown to be neurotoxic.
    Molecular Neurodegeneration 11/2014; 9(1):52. DOI:10.1186/1750-1326-9-52 · 5.29 Impact Factor

Full-text (2 Sources)

Available from
Jun 3, 2014